Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
Letter to company
|
|
CHINA-BIOTICS, INC (CHBT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/29/2012 |
8-K
| Quarterly results |
| 02/29/2012 |
8-K
| Changes in Registrant's Certifying Accountant |
| 10/31/2011 |
8-K
| Form 8-K - Current report |
| 09/20/2011 |
8-K
| Other Events |
| 07/25/2011 |
8-K
| Other Events |
| 06/29/2011 |
8-K
| Form 8-K - Current report |
| 06/28/2011 |
8-K
| Includes a letter to the company / board of directors |
| 06/23/2011 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 06/23/2011 |
8-K
| Changes in Registrant's Certifying Accountant, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
| 03/14/2011 |
8-K
| Form 8-K - Current report |
| 02/10/2011 |
8-K
| Form 8-K - Current report |
| 01/21/2011 |
8-K
| Form 8-K - Current report |
| 12/15/2010 |
8-K
| Form 8-K - Current report |
| 11/17/2010 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/16/2010 |
8-K
| Form 8-K - Current report |
| 07/09/2010 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/11/2010 |
8-K
| Quarterly results |
| 03/10/2010 |
8-K
| Form 8-K - Current report |
| 02/10/2010 |
8-K
| Form 8-K - Current report |
| 01/22/2010 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"China-Biotics, Inc. Appoints New Chief Financial Officer Shanghai, China – January 22, 2010 – China-Biotics, Inc. , a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced the appointment of Mr. Travis Cai as Chief Financial Officer, effective January 22, 2010. Mr. Cai replaces Ms. Eva Yan, who has served as Interim Chief Financial Officer of China-Biotics since Mr. Lewis Fan resigned as Chief Financial Officer on October 21, 2009. Mr. Cai brings more than 10 years of professional and corporate finance experience with public companies and investment institutions. His areas of expertise include financial management, mergers and acquisitions, investor relations, risk controls, SOX 404 compliance, and SE..." |
|
| 12/10/2009 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 Shanghai, China – December 10, 2009 – China-Biotics, Inc. , a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that the Company’s 2009 Annual Meeting of Stockholders will be held on Friday, March 5, 2010 at the Company’s executive offices in Shanghai, China. The Company’s board of directors has established Friday, January 8, 2010 as the record date for determining stockholders entitled to vote at the meeting. Management expects that the definitive proxy statement for the meeting will be mailed to stockholders on or about Friday, January 15, 2010. The time and venue of China-Biotics’ Annual Meeting is as follows: Date..." |
|
| 10/26/2009 |
8-K
| Form 8-K - Current report |
| 10/23/2009 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"China-Biotics, Inc. Announces Changes to Management Team Shanghai, China – October 23, 2009 – China-Biotics, Inc. , a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that Lewis Fan has resigned as Chief Financial Officer in order to pursue other professional interests. Mr. Fan had no disagreements with the Company in regard to its financial statements or accounting matters. His resignation was effective October 21, 2009. The Company is currently searching for qualified candidates to replace Mr. Fan. Ms. Eva Yan, Chief Administration Officer and a director of Shanghai Shining Biotechnology Co. Ltd., a subsidiary of China-Biotics, will serve as interim Chief Financial Officer until a successor is ..." |
|
| 10/05/2009 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"China-Biotics, Inc. Announces Closing of Public Offering of Common Stock Shanghai, China – October 5, 2009 – China-Biotics, Inc. , a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced the closing of its previously announced underwritten public offering. The Company sold 4,600,000 shares of its common stock at $15.00 per share in its public offering, resulting in approximately $65.5 million in net proceeds, after deducting underwriting discounts and commission, but excluding estimated offering expenses. China-Biotics anticipates using the net proceeds from the offering for general corporate purposes, including expanding its retail operations, expanding its products, acquiring additional retail outle..." |
|
| 09/30/2009 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement",
"Opinion of K&L Gates LLP",
"China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock Shanghai, China – September 29, 2009 – China-Biotics, Inc. , a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that it has priced a public offering of 4,600,000 shares of its common stock at $15.00 per share. The shares are being sold under the Company’s previously filed shelf registration statement, which was declared effective by the Securities and Exchange Commission on September 9, 2009. The Company expects that the offering will yield net proceeds, before expenses, of approximately $65,550,000 million and intends to use the net proceeds from the sale of the securities for general corporate purposes, including expanding i..." |
|
| 05/20/2009 |
8-K
| Form 8-K - Current report |
| 03/06/2009 |
8-K
| Form 8-K -- Current report |
| 10/07/2008 |
8-K
| Form 8-K -- Current report |
| 07/15/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/02/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 12/12/2007 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 02/20/2007 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 02/01/2007 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ... |
| 11/14/2006 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
|
|
|